share_log

Alnylam Pharmaceuticals | 8-K: Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity

Alnylam Pharmaceuticals | 8-K: Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity

阿里拉姆制藥 | 8-K：Alnylam Pharmicals公佈2024年第二季度財務業績並重點介紹近期活動
美股SEC公告 ·  2024/08/01 20:16

Moomoo AI 已提取核心訊息

Alnylam Pharmaceuticals delivered robust Q2 2024 financial results with global net product revenues reaching $410 million, representing 34% YoY growth. The performance was primarily driven by its TTR franchise, which grew 37% YoY to $307 million, with AMVUTTRA contributing $230 million. GIVLAARI and OXLUMO generated combined revenues of $103 million, up 25% YoY.The company reported positive topline results from the HELIOS-B Phase 3 study of vutrisiran in ATTR cardiomyopathy patients, demonstrating 28% reduction in composite cardiovascular events and 36% reduction in all-cause mortality. Based on these results, Alnylam plans to submit a supplemental New Drug Application using a Priority Review Voucher.Given the strong performance, Alnylam raised its 2024 financial guidance, increasing combined net product revenue forecast to $1,575-1,650 million from $1,400-1,500 million previously. The company also updated its net revenues from collaborations guidance to $575-650 million, reflecting recent modifications to its Regeneron collaboration agreement.
Alnylam Pharmaceuticals delivered robust Q2 2024 financial results with global net product revenues reaching $410 million, representing 34% YoY growth. The performance was primarily driven by its TTR franchise, which grew 37% YoY to $307 million, with AMVUTTRA contributing $230 million. GIVLAARI and OXLUMO generated combined revenues of $103 million, up 25% YoY.The company reported positive topline results from the HELIOS-B Phase 3 study of vutrisiran in ATTR cardiomyopathy patients, demonstrating 28% reduction in composite cardiovascular events and 36% reduction in all-cause mortality. Based on these results, Alnylam plans to submit a supplemental New Drug Application using a Priority Review Voucher.Given the strong performance, Alnylam raised its 2024 financial guidance, increasing combined net product revenue forecast to $1,575-1,650 million from $1,400-1,500 million previously. The company also updated its net revenues from collaborations guidance to $575-650 million, reflecting recent modifications to its Regeneron collaboration agreement.
阿里拉姆制藥發佈了2024年第二季度強勁的財務業績，全球淨產品營業收入達到41000萬，同比增長34%。業績主要受其TTR業務的推動，同比增長37%，達到30700萬，其中AMVUTTRA貢獻了23000萬。GIVLAARI和OXLUMO的合計營業收入爲10300萬，同比增長25%。該公司報告了來自HELIOS-b 3期研究的積極頂線結果，結果顯示在ATTR心肌病患者中，複合心血管事件減少28%，全因死亡率減少36%。基於這些結果，阿里拉姆計劃提交使用優先審查憑證的補充新藥申請。鑑於強勁的業績，阿里拉姆提高了其2024年的財務指引，將合計淨產品營業收入預測從之前的140000-150000萬上調至157500-165000萬。該公司還更新了其來自合作的淨營業收入指引，調整爲57500-65000萬，反映了與Regeneron合作協議的近期修改。
阿里拉姆制藥發佈了2024年第二季度強勁的財務業績，全球淨產品營業收入達到41000萬，同比增長34%。業績主要受其TTR業務的推動，同比增長37%，達到30700萬，其中AMVUTTRA貢獻了23000萬。GIVLAARI和OXLUMO的合計營業收入爲10300萬，同比增長25%。該公司報告了來自HELIOS-b 3期研究的積極頂線結果，結果顯示在ATTR心肌病患者中，複合心血管事件減少28%，全因死亡率減少36%。基於這些結果，阿里拉姆計劃提交使用優先審查憑證的補充新藥申請。鑑於強勁的業績，阿里拉姆提高了其2024年的財務指引，將合計淨產品營業收入預測從之前的140000-150000萬上調至157500-165000萬。該公司還更新了其來自合作的淨營業收入指引，調整爲57500-65000萬，反映了與Regeneron合作協議的近期修改。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    熱門討論
    特朗普2.0時代開啟，全球市場將如何演變？
    🎙️討論： 1. 關稅政策將如何影響美股、黃金、比特幣等核心資產的走勢？ 2. 在此背景下，有哪些投資機會值得關注？你會如何佈局？ 展开
    MicroStrategy 2024年第4季度業績電話會
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。